GET A PIECE OF PHORMED
PhorMed is a clinical stage biopharmaceutical company, utilizing Gene Repair Therapy to develop our drug RP-323, to treat diseases such as Parkinson’s disease, Acute Myeloid Leukemia, Hodgkin’s Lymphoma and ARDS, caused by COVID-19. PhorMed is pre-revenue and does not currently have a product on the market.
A number of indications are under development which are all categorized as inflammatory disorders. It has been determined that RP-323 is active along specific cell lines, being able to target damaged or mutated cells due to cancer, viruses, and a variety of other factors.
Our studies include cancer cells, blood cells, and, as a result of its special ability to pass through the Blood Brain Barrier (BBB), neurological cells. Because of RP-323’s wide range of activity, the company has been able to build a broad platform from a single molecule.
The company is working on a treatment for Parkinson’s disease that we believe is in line to become one of the top innovative therapies. RP-323 is also targeted to be a first-line treatment in Oncology, Neurology, and Anti-Virus. The company’s mission is to treat unmet medical needs by treating the cause, and in some cases, the symptom.
This is accomplished through differentiation, RP-323’s ability to repair the DNA of damaged or mutated cells; immunotherapy, boosting the body’s immune system through cytokine induction; and by stem cell signaling and proliferation, stimulating cell division once the cell is repaired and functioning properly. All of these mechanisms work in unison allowing the body to heal and return to a healthy condition.
Five indications are presently in the pipeline and the company will continue to expand through its continued dedication in research and development. We are committed to the highest standards of scientific excellence and integrity to accomplish these goals for our patients and society.
Patient options are frequently limited and at times no known effective options are available.
With patients suffering from Acute Myeloid Leukemia (AML) or Hodgkin’s Lymphoma (HL), chemotherapy has been the traditional option which is well known to have harmful or lethal side effects, while those with Parkinson’s disease (PD) and Acute Respiratory Distress Syndrome (ARDS), caused by COVID-19 are faced with no realistic treatment options. PhorMed is attempting to offer NEW FIRST-LINE TREATMENTS in these areas allowing patients new hope. (source, source, source, source)
We are looking to offer new treatments for AML, HL, PD, and ARDS caused by COVID-19. Our goal is to make faster acting treatments that are safer for patients, and to make chemotherapy obsolete in our selected markets.
We focus on treating diseases through Gene Repair Therapy
RP-323 utilizes Gene Repair Therapy to target damaged or mutated cells and repair a broad range of cell types. Our technology focuses on the root cause, aiming to fix the cellular damage on a molecular level.
The drug will be administered through intravenous infusion.
The world market for drugs treating HL is projected to post a compound annual growth rate (CAGR) of 14.75% for the forecast period of 2022-2026. The same projections expect the market to reach $1.85 billion by 2026.
The CAGR of the AML market is expected to be around 14% over the next five years, and is expected to top $2.22 billion by 2026.
The PD world drug market is expected to reach $8.38 billion at CAGR of 8.1% by 2026.
Combined, the total annual market for three of our drug's potential uses could reach close to $12.45 billion by 2026.
The COVID-19 market is still to be determined.
Initial studies have shown our treatments are non-toxic with limited side effects.
Chemotherapy has long-lasting and potentially devastating side effects and can severely damage and kill healthy cells.
Depending on the severity of a disease when our drug is administered, a majority of treatment recipients will not be required to have hospital stays thanks to the limited side effects and unobtrusive nature of the drug. We believe our treatment will be a safer and non-toxic alternative for a variety of applications including cancer, viruses and neurological disorders.
Our drug has been found to be safe for use in humans after the completion of the Phase 1 study. We are allocating a large majority of our funds towards clinical research and are actively proceeding with next steps in clinical research for all our indications.
RP-323 originally conducted a Phase I trial in 2004-2005. For human FDA trials, there are only three phases prior to entering into the marketplace. Those are Phase 1, Phase 2, Phase 3. Once Phase 1 is complete, the FDA may require an abbreviated safety phase to be included within the Phase 2 study which they call phase 1/2 or I/II. The 1 (I) portion of 1/2 (I/II) is an abbreviated safety step. Once the abbreviated safety step is completed companies move directly to starting Phase 2 (II). As of 2022, PhorMed is currently in phase 1/2 (I/II). We are not currently active in a trial at this time however we are in preparation for this next phase.
With your help and proper funding, we expect to eventually complete Phase 2 in all our clinical trials and move into the last stages of testing and finally into the hands of patients who need better options.
We are driven to replace Chemotherapy as a first-line treatment offering doctors and patients better options.
We are looking to offer patients a safe and effective way to better health and treatment methods with fewer side effects. We strive to make medical treatment less costly and available to all by reducing or eliminating the need for hospital stays.
We have an opportunity to improve the path patients take to recovery. With your help, we can make chemotherapy a thing of the past.
We believe our technology is the future of medicine. With your financial support we can pave the way to a healthier future with lower medical costs by eliminating or reducing the need for hospital stays, and moving medicine forward into modern times.
PhorMed is a Biotech Company paving the way in the advancement of a Gene Repair Therapy with our lead drug internally called RP-323. Our drug has the ability to repair cells allowing the body to recover. We are looking to treat a variety of disorders such as Parkinson’s disease, Acute Myeloid Leukemia, Hodgkin’s Lymphoma and Acute Respiratory Distress Syndrome, caused by COVID-19
Prof. Richard L. Chang
Inventor and CSO
• Inventor and holder of multiple patents
• 124 peer-reviewed journal publications
• 150+ Scientific Abstracts
• Holder of 9 Patents
Professor Chang has filed multiple significant patents for the treatment of cancer, infectious disease, hematology, and neurological disorders. Prof. Chang has over 53 years of research experience with such companies as Hoffman-La-Roche, Schering Corp, and Burroughs Wellcome and is a full professor and director of Research at Rutgers University. He successfully launched and completed off IND and IND phase I trials in China and US.
CEO, CFO, President, Director
• 16+ years of executive level experience in Biotech business ventures
• Holder of 2 patents
Mr. Chang has previously been founder, director, CEO, President, CFO, and/or COO of such biotech companies as Biosuccess Biotech Co. LTD., Rich Pharmaceuticals, Inc., and HypGen, Inc. Mr. Chang started his life-science career as the founder and managing partner of Sun-Rich Chemicals, product development and distribution organization for nutraceuticals. Mr. Chang also has experience in international banking, venture capital, M&A, finance, go-public transactions, and organizational design and operations. Mr. Chang has a Bachelor of Science Degree in Economics from East Carolina University where he focused on accounting and international business.
Carole A. Salvador, Psy.D.
Sean M. O’Connell, Ph.D
Chief Medical Officer
• 65+ peer reviewed publications
Dr. O'Connell has served as CSO, CMO, Chief Scientist, SVP, and Founder of multiple pharmaceutical and research companies such as Novartis Pharmaceuticals, Vertical Spine, LLC., Cascade Medical Enterprises, and Integrated Communications Corp. (ICC/IPG). He has received numerous research grants and currently holds the position of Adjunct Professor in the Department of Vascular Surgery, Englewood Hospital and Medical Center, Mount Sinai School of Medicine, New York. He received his PhD in immunology and molecular biology from Rutgers University and the University of Medicine and Dentistry of New Jersey at New Brunswick (now Rutgers Medical school).
VP of Marketing & Business Development (Part-Time)
Steven J. Davis
McCoy Moretz M.D.
Maximum Number of Shares Offered subject to adjustment for bonus shares
*Maximum Number of Shares Offered subject to adjustment for bonus shares. See Bonus info below.
Invest within the first week and receive 20% bonus shares.
Invest within the first two weeks and receive 15% bonus shares.
Invest within the first three weeks and receive 10% bonus shares.
Invest within the first four weeks and receive 5% bonus shares.
$1,000+ | 5% Bonus Shares
Invest $1,000+ to receive 5% bonus shares & access to our Investor Club which allows you to vote on drug names, and receive special investor updates.
$5,000+ | 10% Bonus Shares
Invest $5,000+ to receive 10% bonus shares & access to our Investor Club.
$10,000+ | 15% Bonus Shares
Invest $10,000+ to receive 15% bonus shares & access to our Investor Club.
*All perks occur when the offering is completed.
PhorMed, Inc. will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.
This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Common Stock at $1.00 / share, you will receive 110 shares of Common Stock, meaning you'll own 110 shares for $100. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.
This 10% Bonus is only valid during the investors eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.
Investors will receive the highest single bonus they are eligible for among the bonuses based on the amount invested and time of offering elapsed (if any). Eligible investors will also receive the Owner’s Bonus and the 10% Loyalty Bonus Perk for all previous Crowdfunding offering 1 investors on StartEngine in addition to the aforementioned bonus.
Irregular Use of Proceeds
The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000: Vendor payments. Salary payments made to one’s self, a friend or relative. Any expense labeled “Travel and Entertainment”.
Members get an extra 10% shares in addition to rewards below!
4 months ago
9 months ago
a year ago
a year ago
a year ago
a year ago
a year ago
a year ago
a year ago
a year ago
Cancel anytime before 48 hours before a rolling close or the offering end date.
We want you to succeed and get the most out of your money by offering rewards and memberships!
Your info is your info. We take pride in keeping it that way!
Invest in over 200 start-ups and collectibles!
With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.
With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.
At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.
Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.
StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.
For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.
For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.
Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.
Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.
Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.